Use your antibodies-online credentials, if available.
Il n’y a pas de produits dans votre liste de comparaison.
Votre panier est vide.
Afficher toutes les espèces
Afficher tous les synonymes
Sélectionnez vos espèces et l'application
anti-Human LIMD1 Anticorps:
anti-Mouse (Murine) LIMD1 Anticorps:
anti-Rat (Rattus) LIMD1 Anticorps:
Vous arrivez à notre recherche pré-filtrée.
that the reduced expression of LimD1 and VHL (Montrer VHL Anticorps) might have synergistic effect on induction of HIF1alpha (Montrer HIF1A Anticorps) resulting increased cellular proliferation and progression of the disease.
our data also suggests the importance ofLIMD1 and CDC25A (Montrer CDC25A Anticorps) in conjunction with HPV for use as diagnostic and prognostic markers of HNSCC, whereas RBSP3 (Montrer CTDSPL Anticorps) as a prognostic marker only.
LIMD1 coordinates the assembly of an AGO-TNRC6 containing miRISC complex by binding both proteins simultaneously at distinct interfaces.
These results suggested that LIMD1 is a novel BRCA2-interacting protein and is involved in the centrosome localization of BRCA2 (Montrer BRCA2 Anticorps) and suppression of LIMD1, causing abnormal cell division in EC cells.
Thus, the LIMD1-MYBL1 (Montrer MYBL1 Anticorps) Index had considerable clinical value for DLBCL subtype classification and prognosis.
Cyclic stretch is associated with a JNK (Montrer MAPK8 Anticorps)-dependent increase in binding of a LATS (Montrer LATS1 Anticorps) inhibitor, LIMD1, to the LATS1 (Montrer LATS1 Anticorps) kinase and that reduction of LIMD1 expression suppresses the activation of YAP (Montrer YAP1 Anticorps) by cyclic stretch.
LIMD1 prevents retinoblastoma phosphorylation and downregulates of E2F1 (Montrer E2F1 Anticorps) protein and blocks entry of cells into S-phase.
Data show that the tumour suppressor protein LIMD1 acts as a molecular scaffold, simultaneously binding the PHDs and VHL (Montrer VHL Anticorps), thereby assembling a PHD (Montrer PDC Anticorps)-LIMD1-VHL (Montrer VHL Anticorps) protein complex and creating an enzymatic niche that enables efficient degradation of HIF-1alpha (Montrer HIF1A Anticorps).
PU.1 is a major transcriptional activator of LIMD1
LIMD1 inactivation as primary event than inactivation of RB1 (Montrer RB1 Anticorps) in head and neck squamous cell carcinoma development.
Limd1 regulates AP-1 (Montrer JUN Anticorps) activation through an interaction with Traf6 (Montrer TRAF6 Anticorps) to influence osteoclast development
Limd1 influences not only stress osteoclastogenesis but also osteoblast function and osteoblast progenitor commitment. Together, these data identify Limd1 as a novel regulator of both bone osetoclast and bone osteoblast development and function.
Adapter or scaffold protein which participates in the assembly of numerous protein complexes and is involved in several cellular processes such as cell fate determination, cytoskeletal organization, repression of gene transcription, cell-cell adhesion, cell differentiation, proliferation and migration. Positively regulates microRNA (miRNA)-mediated gene silencing and is essential for P-body formation and integrity. Acts as a hypoxic regulator by bridging an association between the prolyl hydroxylases and VHL enabling efficient degradation of HIF1A. Acts as a transcriptional corepressor for SNAI1- and SNAI2/SLUG- dependent repression of E-cadherin transcription. Negatively regulates the Hippo signaling pathway and antagonizes phosphorylation of YAP1. Inhibits E2F-mediated transcription, and suppresses the expression of the majority of genes with E2F1- responsive elements. Regulates osteoblast development, function, differentiation and stress osteoclastogenesis. Enhances the ability of TRAF6 to activate adapter protein complex 1 (AP-1) and negatively regulates the canonical Wnt receptor signaling pathway in osteoblasts. May act as a tumor suppressor by inhibiting cell proliferation (By similarity).
LIM domain-containing protein 1
, LIM domains-containing protein 1